Treat-to-target With Secukinumab in Axial Spondyloarthritis
NCT03639740
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
88
Enrollment
OTHER
Sponsor class
Conditions
Axial Spondyloarthritis
Ankylosing Spondylitis
Interventions
DRUG:
Secukinumab 150 milligram [Cosentyx]
Sponsor
Professor Mikkel Østergaard
Collaborators
[object Object]